Personalised Treatments in MS (Brown Group)
Led by a panel of expert patients, we use big data and cutting-edge artificial intelligence to identify the right drug, for the right person at the right time.
We enable everyone in the UK to participate in the most crucial research, and we reduce healthcare inequalities.
Learn more about our projects below.
Meet the Group
Learn a little more about each member of the Personalised Treatments group by clicking on their profile picture below.
.png)
_edited.jpg)
Publications
Click the journal covers or paper titles below to view the key publications to which members of the Personalised Treatments in MS group have contributed.
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis
Remyelination varies between and within lesions in multiple sclerosis following bexarotene
Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependent
Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic
Determinants of therapeutic lag in multiple sclerosis
Surface-in pathology in multiple sclerosis: a new view on pathogenesis?
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Keratinocyte growth factor impairs human thymic recovery from lymphopenia
An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis
Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
Funding
The current funding sources for the Personalised Treatments in MS group are shown below.
Delivering state-of-the-art MRI results automatically into healthcare records to improve care and transform research in multiple sclerosis: a pilot study
2024-07 to 2026-06 | Grant
MS Society (London, GB)
Epic neuroimmunology smartform and CONSENTOR
2024-01 to 2026-01 | Grant
Roche Pharmaceutical (Basel, CH), Sanofi (Paris, FR), Novartis Pharmaceuticals UK Limited (London, GB)
Installing and overseeing an open-source software platform (XNAT) to enable reliable and efficient imaging processing for Cambridge Neuroscience
2023-06 to 2025-05 | Grant
NIHR Cambridge Biomedical Research Centre (Cambridge, GB)
A 12-site retrospective observational study of real-world fumarate tolerability
2022-12 to present | Grant
Biogen IDEC (MA, MA, US)
Improving the long-term outcomes for people with multiple sclerosis by studying real-world data
2022-03-01 to 2027-02-28 | Grant
NIHR Academy (Leeds, GB)